[go: up one dir, main page]

MXPA02004327A - Metodos y composiciones para potenciar los agentes quimioterapeuticos contra cancer. - Google Patents

Metodos y composiciones para potenciar los agentes quimioterapeuticos contra cancer.

Info

Publication number
MXPA02004327A
MXPA02004327A MXPA02004327A MXPA02004327A MXPA02004327A MX PA02004327 A MXPA02004327 A MX PA02004327A MX PA02004327 A MXPA02004327 A MX PA02004327A MX PA02004327 A MXPA02004327 A MX PA02004327A MX PA02004327 A MXPA02004327 A MX PA02004327A
Authority
MX
Mexico
Prior art keywords
chemotherapeutic agents
compositions
methods
cancer chemotherapeutic
potentiating
Prior art date
Application number
MXPA02004327A
Other languages
English (en)
Inventor
J Jariwalla Raxit
Original Assignee
Oxycal Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxycal Lab Inc filed Critical Oxycal Lab Inc
Publication of MXPA02004327A publication Critical patent/MXPA02004327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El efecto de los agentes quimioterapeuticos contra cancer se potencia mediante la combinacion con ascorbatos minerales, metabolitos de la vitamina C y/o una furanona derivada de la vitamina C, por ejemplo una 4-hidroxi-5-metil-3(2H)furanona.
MXPA02004327A 2000-09-01 2001-08-24 Metodos y composiciones para potenciar los agentes quimioterapeuticos contra cancer. MXPA02004327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/654,377 US6468980B1 (en) 2000-09-01 2000-09-01 Methods and compositions for potentiating cancer chemotherapeutic agents
PCT/US2001/026455 WO2002020023A1 (en) 2000-09-01 2001-08-24 Methods and compositions for potentiating cancer chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA02004327A true MXPA02004327A (es) 2002-11-07

Family

ID=24624611

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004327A MXPA02004327A (es) 2000-09-01 2001-08-24 Metodos y composiciones para potenciar los agentes quimioterapeuticos contra cancer.

Country Status (15)

Country Link
US (1) US6468980B1 (es)
EP (1) EP1286674B1 (es)
JP (1) JP2004508335A (es)
KR (1) KR20030019297A (es)
AT (1) ATE400267T1 (es)
AU (1) AU8525401A (es)
CA (1) CA2389602A1 (es)
CY (1) CY1108787T1 (es)
DE (1) DE60134740D1 (es)
DK (1) DK1286674T3 (es)
ES (1) ES2309085T3 (es)
MX (1) MXPA02004327A (es)
PT (1) PT1286674E (es)
TR (1) TR200201192T1 (es)
WO (1) WO2002020023A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878744B2 (en) * 1999-02-05 2005-04-12 Oxycal Laboratories, Inc. Vitamin C compositions
CN1197561C (zh) * 2001-07-03 2005-04-20 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗损及软骨的疾病的药物中的用途
WO2005018633A1 (en) 2003-08-13 2005-03-03 Oxycal Laborataries, Inc. Methods for the amelioration of environmental oxidant stress and the regulation of beneficial genes
NZ578693A (en) * 2007-01-31 2011-08-26 Univ Rutgers Controlled release of actives in skin
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
TR2022000209A2 (tr) 2022-01-07 2022-02-21 Oezge Gueven Ozoni̇ze c-vi̇tami̇ni̇ i̇çeren bi̇r anti̇-kanser i̇laci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6846687A (en) * 1985-12-05 1987-06-30 American Biotechnology Co. Ltd. Anthracycline type antitumor agents with l-ascorbic acid
GB8810173D0 (en) * 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
WO1990012571A1 (en) * 1989-04-07 1990-11-01 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin c
JPH08291075A (ja) * 1995-04-20 1996-11-05 Showa Denko Kk 癌転移阻害剤
EP0875246A1 (en) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer
PT982990E (pt) * 1998-02-06 2007-01-31 Ester C Company Composições líquidas estáveis de ascorbato de cálcio e métodos de preparação e utilização
DE69939123D1 (de) * 1999-08-30 2008-08-28 Ester C Company Verwendungen und zusammensetzungen für selektive krebs-chemotherapie

Also Published As

Publication number Publication date
CA2389602A1 (en) 2002-03-14
KR20030019297A (ko) 2003-03-06
EP1286674A1 (en) 2003-03-05
CY1108787T1 (el) 2014-04-09
ES2309085T3 (es) 2008-12-16
EP1286674A4 (en) 2005-12-21
AU8525401A (en) 2002-03-22
TR200201192T1 (tr) 2003-05-21
WO2002020023A1 (en) 2002-03-14
PT1286674E (pt) 2008-08-21
US6468980B1 (en) 2002-10-22
ATE400267T1 (de) 2008-07-15
EP1286674B1 (en) 2008-07-09
DE60134740D1 (de) 2008-08-21
DK1286674T3 (da) 2008-11-03
JP2004508335A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2795000A (en) Epothilone derivatives and their use as antitumor agents
AU3652102A (en) Compounds and their uses
DE60112974D1 (en) Carbolinderivate
AU2001282399A1 (en) Resorcinol derivatives
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
BG105967A (en) C(7) ester substituted taxanes and their use as antitumor agents
EA200100369A1 (ru) Химиотерапия рака с помощью ацетилдиналина в комбинации с гемцитабином, кэйпцитабином или цис-платиной
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
BG106738A (en) A method for chemoprevention of prostate cancer
DE60216233D1 (en) Carbolinderivate
IL145639A0 (en) C10 heterosubstituted acetate taxanes as antitumor agents
CY1108787T1 (el) Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
WO2002080854A3 (en) Compositions and methods for the prevention and treatment of human prostate cancer
AP2001002274A0 (en) Rescorcinol derivatives.
IL138688A0 (en) Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
MY136518A (en) Use of triazine trione sulphones for controlling coccidioses
WO2002062334A3 (en) Cancer chemopreventative compounds and compositions and methods of treating cancers
MXPA04005942A (es) Composiciones y metodos de sintaxina 3.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE69815100D1 (de) Zusammensetzungen, die dolastatin-15-analoge in kombination mit taxane und dessen derivaten enthalten
BG105966A (en) C7 carbonate substituted taxanes and their application as antitumor agents
TR200302193T4 (tr) Kombinasyon kemoterapisi.
IL145640A0 (en) C10 carbamoyloxy substituted taxanes as antitumor agents
PL351380A1 (en) C10 ester substituted taxanes as antitumor agents

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status
HC Change of company name or juridical status